Palbociclib

COMPOSITION:

Each capsule contains Palbociclib………………………….. 100mg.

Each capsule contains Palbociclib………………………….. 125mg.

INDICATION:

LuciPalbo is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men; or fulvestrant in patients with disease progression following endocrine therapy.

DOSAGE AND USE:

LuciPalbo capsules are taken orally with food in combination with an aromatase inhibitor or fulvestrant.

• Recommended starting dose: 125 mg once daily taken with food for 21 days followed by 7 days off treatment.

• Dosing interruption and/or dose reductions are recommended based on individual safety and tolerability.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY:

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciPalbo during Pregnancy and Lactation.